Cardiff Oncology Inc
NASDAQ:CRDF
Cardiff Oncology Inc
Operating Income
Cardiff Oncology Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cardiff Oncology Inc
NASDAQ:CRDF
|
Operating Income
-$45.4m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-16%
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$16.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$8.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$7.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$3.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
See Also
What is Cardiff Oncology Inc's Operating Income?
Operating Income
-45.4m
USD
Based on the financial report for Dec 31, 2023, Cardiff Oncology Inc's Operating Income amounts to -45.4m USD.
What is Cardiff Oncology Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-16%
Over the last year, the Operating Income growth was -14%. The average annual Operating Income growth rates for Cardiff Oncology Inc have been -33% over the past three years , -23% over the past five years , and -16% over the past ten years .